The new Eurosurveillance website is almost here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2011: Volume 16/ Issue 23 Article 1
Back to Table of Contents
Download (pdf)

Eurosurveillance, Volume 16, Issue 23, 09 June 2011
Rapid communications
Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation
  1. World Health Organization Collaborating Centre for Reference and Research on Influenza, North Melbourne, Victoria, Australia
  2. Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), Singapore
  3. National Public Health Laboratory, Communicable Diseases Division Ministry of Health, Singapore
  4. Serology/Molecular Biology Department, Royal Darwin Hospital, Darwin, Australia
  5. PathWest Laboratory Medicine, Nedlands, Western Australia
  6. School of Biological Sciences (SBS), Nanyang Technological University (NTU), Singapore

Citation style for this article: Hurt AC, Lee RT, Leang SK, Cui L, Deng YM, Phuah SP, Caldwell N, Freeman K, Komadina N, Smith D, Speers D, Kelso A, Lin RT, Maurer-Stroh S, Barr IG. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill. 2011;16(23):pii=19884. Available online:
Date of submission: 26 May 2011

A novel influenza A(H1N1)2009 variant with mildly reduced oseltamivir and zanamivir sensitivity has been detected in more than 10% of community specimens in Singapore and more than 30% of samples from northern Australia during the early months of 2011. The variant, which has also been detected in other regions of the Asia-Pacific, contains a S247N neuraminidase mutation. When combined with the H275Y mutation, as detected in an oseltamivir-treated patient, the dual S247N+H275Y mutant had extremely high oseltamivir resistance.


The emergence and global spread in 2007/08 of an oseltamivir-resistant seasonal influenza A(H1N1) variant containing a histidine to tyrosine substitution (H275Y) in the neuraminidase (NA), demonstrated the potential for drug-resistant influenza viruses to arise and spread within the community in the absence of drug-selective pressure [1]. Since the start of the 2009 pandemic, the oseltamivir-resistant H275Y variant has only been detected on rare occasions in pandemic influenza A(H1N1)2009 community specimens (<1%), although recent reports have suggested that this frequency may be increasing [2]. Other NA mutations in influenza A(H1N1)2009 viruses have been reported to confer mildly reduced oseltamivir and/or zanamivir sensitivity, such as substitutions at the isoleucine residue at position 223 (N1 numbering), but the detection of these mutants has been very rare and has occurred mostly in isolated cases of immunocompromised individuals under long-term NA inhibitor (NAI) treatment [3,4]. Here we report the identification and increased rate of detection in community samples of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity. The variant contained a serine to asparagine mutation at residue 247 (S247N) of the NA, and has been detected in recent community specimens from Australia, Brunei and Singapore. Although the mutation has been described before in a small number of seasonal influenza A(H1N1) and highly pathogenic influenza A(H5N1) viruses with reduced NAI sensitivity [5,6], it has not previously been reported in influenza A(H1N1)2009 viruses, and has not occurred in any strains at the frequencies that are described here.

Materials and methods

Specimens and isolates from the Asia-Pacific region were submitted to the World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza, Melbourne, as part of the WHO Global Influenza Surveillance Network. Isolates cultured in Madin-Darby canine kidney (MDCK) cells were analysed for oseltamivir, zanamivir and peramivir sensitivity using a fluorescence-based neuraminidase inhibition assay [7]. Oseltamivir carboxylate, the active form of the ethyl ester prodrug oseltamivir phosphate, was kindly provided by Hoffmann-La Roche Ltd, Switzerland; zanamivir was kindly provided by GlaxoSmithKline, Australia; peramivir was kindly provided by BioCryst, United States. Isolates and specimens were sequenced using standard techniques at the WHO Collaborating Centre, Melbourne, except for Singaporean strains which were sequenced at the National Public Health Laboratory, Singapore. Haemagglutinin (HA) and NA sequences reported here have been deposited on GISAID (; accession numbers EPI319165 to EPI319183) or GenBank (accession numbers CY091664 to CY091724 and CY063853 to CY063854). Other HA and NA sequences were analysed from GISAID or Genbank sequence databases (see supplementary* for details: A concatenated HA and NA nucleotide alignment was created with MAFFT (FFT-NS-2) ( and a maximum likelihood phylogenetic tree was generated with PhyML ( using the HKY85 substitution model, 4 gamma-distributed categories (shape parameter 0.46) and the approximate likelihood ratio test. The trees were visualised and annotated in MEGA5 (

The S247N and dual S247N+H275Y NA mutations were investigated further by site-directed mutagenesis and reverse genetics using the eight-plasmid system. Mutations were engineered into the NA of influenza A/Auckland/1/2009(H1N1) and transfected together with plasmids containing the seven remaining segments from the influenza A/Puerto Rico/8/34 strain, as described previously [8].

The mutations S247N and H275Y were modelled into the influenza A(H1N1)2009 neuraminidase crystal structure and the effects of the mutations on oseltamivir binding were visualised and examined using FoldX ( and Yasara (


From April 2009 to December 2010, over 2,900 influenza A(H1N1)2009 influenza viruses from the Asia-Pacific region were analysed for NAI sensitivity with only 23 H275Y oseltamivir-resistant viruses detected (0.8%), and virtually all of the remaining strains being fully sensitive to both oseltamivir and zanamivir. However since December 2010, 22 influenza A(H1N1)2009 viruses containing a novel S247N NA mutation (S246N based on N2 numbering), have been detected in both clinical specimens and isolates from the Asia-Pacific region. The majority of the S247N variants detected since December 2010 (n=19) have occurred in two clusters, one in the Darwin region in northern Australia and the other in Singapore (Figure 1A). The variant has also been detected in Western Australia and Brunei (in this study), and based on data from the public sequence databases has occurred, albeit rarely, in other locations such as the United States, Europe and Asia since 2009 (Figure 1A). During the first three months of 2011, 28 influenza A(H1N1)2009 strains were sampled from the Darwin region, of which nine contained the S247N mutation, while in Singapore 10 out of 80 viruses sampled since December 2010 had the S247N NA mutation (Figure 1B).

Figure 1. Detection of influenza A(H1N1)2009 S247N variants since 2009**

Of the 22 S247N variants detected, nine were cultured and in an NA inhibition assay showed a mean six-fold reduction in oseltamivir sensitivity, a three-fold reduction in zanamivir sensitivity, and no significant reduction in peramivir sensitivity compared to the mean IC50 (concentration required to inhibit 50% of NA activity) of sensitive influenza A(H1N1)2009 viruses (Table).

Table. Neuraminidase inhibitor sensitivity of naturally occurring and recombinant S247N and S247N+H275Y influenza A(H1N1)2009 variants,  December 2010–March 2011

In Perth, Western Australia, an immunocompromised patient was found on 1 March 2011 to be infected with an influenza virus that contained the S247N NA mutation (A/Perth/30/2011) (Table). Oseltamivir treatment was commenced two days after detecting the initial S247N variant (3 March). A sputum specimen collected five days later (8 March) contained an influenza virus with both the S247N and H275Y NA mutations (A/Perth/29/2011) (Table). Despite commencement of intravenous zanamivir the patient died on 16 March from multiple organ failure. The isolate with the dual S247N and H275Y mutations had an oseltamivir IC50 nearly 6,000-fold higher than sensitive viruses and 10-fold higher than seen for influenza A(H1N1)2009 viruses with the H275Y mutation alone (Table). Clonal analysis of the virus population from the sputum specimen collected after oseltamivir treatment confirmed that both the S247N and H275Y mutations occurred together in the NA. The effect of the S247N and dual S247N and H275Y mutations on NAI sensitivity was confirmed by reverse genetics experiments (Table).

Sequence analysis of the S247N variants from the recent Darwin and Singapore clusters revealed that the majority belonged to the same genetic lineage (Figure 2). The two strains from the immunocompromised patient in Perth were also genetically similar to the Darwin and Singapore strains, but the virus from Brunei and one strain from Singapore were placed in a separate clade together with one other S247N strain from the United States (Figure 2).

Figure 2. Phylogenetic trees of concatenated haemagglutinin and neuraminidase sequences from influenza A(H1N1)2009 S247N variants detected December 2010-March 2011

Structural analyses indicate that the S247N mutation could change the hydrogen bonding network and side chain conformation of residue E277 (E276 by N2 numbering) reflecting similar but weaker alterations known from the H275Y mutation. When adding H275Y, E277 gets pushed further into the drug binding pocket which is believed to weaken oseltamivir binding (Figure 3).

Figure 3. The structural effect of the S247N and S247N+H275Y mutations in the neuraminidase of influenza A(H1N1)



Previous studies have reported the effect of the S247N mutation on NAI sensitivity in N1 neuraminidases. The levels of oseltamivir and zanamivir sensitivity reported for the S247N mutation in a pre-pandemic seasonal influenza A(H1N1) virus were similar to those reported here for the mutation in influenza A(H1N1)2009 strains [5]. However a greater reduction in oseltamivir sensitivity was reported for a highly pathogenic influenza A(H5N1) strain with a S247N mutation compared to the influenza A(H1N1)2009 strains reported here (24-fold vs 6-fold reduction compared to their respective wildtypes) [6]. The same study also reported on an influenza A(H5N1) virus with the S247N and two additional mutations, I223L and K150N (N1 numbering). This triple mutant virus had a greater reduction in oseltamivir sensitivity compared to the S247N mutation alone (77-fold vs 24-fold reduction), further demonstrating that mutations at other key residues such as I223, in combination with S247N, can cumulatively decrease NAI sensitivity. Given that a number of studies have recently reported I223 mutations conferring NAI resistance in influenza A(H1N1)2009 strains [3,4,9,10], and that data from the United Kingdom show an increased frequency of H275Y mutants in community samples [2], the likelihood of mutation combinations S247N+I223X and S247N+H275Y is considerably increased  if the S247N influenza A(H1N1)2009 variant continues to spread.

Pharmacokinetic data would suggest that the maximum drug levels achieved via the recommended dose easily exceed the observed IC50 values of the S247N mutant [11], and therefore the variant is unlikely to be clinically resistant. However, it is noteworthy that recent clinical studies have demonstrated a reduced oseltamivir efficacy for normal influenza B viruses [12] which have IC50 values only 6-fold higher than that of the S247N influenza A(H1N1)2009 variants (mean oseltamivir IC50±SD for influenza B viruses from 2010 and 2011: 15.5 nM±11.3 (n=557)). Data from Singapore and Darwin demonstrate that the S247N variant is able to circulate widely and therefore does not appear to have compromised viral fitness or transmissibility. If the S247N variant spreads globally, the greatest concern is that other NA mutations which may have previously caused only mild reductions in NAI susceptibility (e.g. mutations at the I223 residue) could instead cumulatively decrease NAI sensitivity to levels that may be clinically significant and affect treatment efficacy. Laboratories should consider screening currently circulating specimens and isolates for the S247N NA mutation to determine whether the variant is spreading into other regions.

*Note: Supplementary information made available by the authors on an independent website is not edited by Eurosurveillance, and Eurosurveillance is not responsible for the content.

The authors wish to thank the various laboratories that submit specimens and isolates to the Melbourne WHO Collaborating Centre for Reference and Research on Influenza. The reverse genetics plasmid pHW2000 was kindly provided by Dr Richard Webby, St Jude Children’s Research Hospital, Memphis, United States. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health and Ageing.

**Erratum: The map in Figure 1 was misaligned with the dots. This was corrected on 10 June 2011.



  1. Meijer A, Lackenby A, Hungnes O, Lina B, van der Werf S, Schweiger B, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis. 2009;15(4):552-60.
  2. Lackenby A, Moran Gilad J, Pebody R, Miah S, Calatayud L, Bolotin S, et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro Surveill. 2011;16(5):19784. Available from:
  3. van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med. 2010;363(14):1381-2.
  4. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis. 2010;51(8):983-4.
  5. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52(9):3284-92.
  6. Boltz DA, Douangngeun B, Phommachanh P, Sinthasak S, Mondry R, Obert C, et al. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J Gen Virol. 2010;91(Pt 4):949-59.
  7. Hurt AC, Barr IG, Hartel G, Hampson AW. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res. 2004;62(1):37-45.
  8. Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother. 2009;53(10):4433-40.
  9. Rousset D, Le Goff J, Abou-Jaoude G, Molina JM, Scemla A, Caro V, et al. Emergence of succesive mutations in the neuraminidase of the pandemic H1N1 virus respectively associated with oseltamivir resistance and reduced susceptbility to both oseltamivir and zanamivir under treatment with neuraminidase inhibitors. Options for the Control of Influenza VII; 2010; Hong Kong. Abstract Book. P-198.
  10. Santos L, Correia V, Giria M, Pedro S, Santos M, Silvestre M, et al. Genetic and antiviral drug susceptbility profiles of pandemic A(H1N1)v influenza virus circulating in Portugal. Options for the Control of Influenza VII; 2010; Hong Kong. Abstract Book.O-851.
  11. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999;37(6):471-84.
  12. Sugaya N, Mitamura K, Yamazaki M, Tamura D, Ichikawa M, Kimura K, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis. 2007;44(2):197-202.

Back to Table of Contents
Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.